Recent investigations have centered on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine signaling. While GLP agonists are widely employed for addressing type 2 diabetes mellitus, their potential impacts on reward circuits, specifically governed by DA systems, are receiving substanti… Read More